Coherus Oncology, Inc. Common Stock (CHRS) is a publicly traded Healthcare sector company. As of May 21, 2026, CHRS trades at $1.52 with a market cap of $229.83M and a P/E ratio of 0.92. CHRS moved +2.36% today. Year to date, CHRS is +4.86%; over the trailing twelve months it is +85.03%. Its 52-week range spans $0.66 to $2.62. Analyst consensus is strong buy with an average price target of $8.25. Rallies surfaces CHRS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Coherus Oncology, Inc. Common Stock (CHRS) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. CHRS moved +2.36% today. Analyst consensus is strong buy.
| Metric | Value |
|---|---|
| Price | $1.52 |
| Market Cap | $229.83M |
| P/E Ratio | 0.92 |
| EPS | $1.64 |
| Dividend Yield | 0.00% |
| 52-Week High | $2.62 |
| 52-Week Low | $0.66 |
| Volume | 71 |
| Avg Volume | 0 |
| Revenue (TTM) | $46.88M |
| Net Income | $186.27M |
| Gross Margin | 68.06% |
5 analysts cover CHRS: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $8.25.